Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714863 | 0.78 | AHR (0.42) | AHRPTGER1PTGER3PTGER2SLC6A2 | |
| SCHEMBL6427994 | 0.73 | PTGER1 (0.41) | AHRPTGER1PTGER3PTGER2PTGER4 | |
| SCHEMBL9086179 | 0.72 | BDKRB1 (0.45) | PTGER1PTGER3PTGER2NOTUMSLC6A2 | |
| SCHEMBL1154775 | 0.72 | AHR (0.44) | AHRCD274PTGER1PTGER3PTGER2 | |
| SCHEMBL2345310 | 0.70 | CD274 (0.43) | CD274PDCD1 | |
| SCHEMBL9444928 | 0.68 | AHR (0.43) | AHRPTGER1PTGER3PTGER2PTGER4 | |
| SCHEMBL11136480 | 0.68 | AHR (0.46) | AHRPTGER1PTGER3PTGER2PTGER4 | |
| SCHEMBL7559810 | 0.68 | ALDH1A1 (0.40) | CD274NOTUMSLC6A4SLC6A3PDCD1 | |
| SCHEMBL9288019 | 0.67 | TRPA1 (0.49) | AHRPTGER1PTGER3PTGER2SLC6A2 | |
| SCHEMBL9444900 | 0.66 | CYP4F2 (0.55) | PTGER1PTGER3PTGER2PTGER4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178342-A1 | Solid Pharmaceutical Preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050154009-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20100210626-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | FRIEDL THOMAS | 2010-08-19 | — | — | US | disclosed |
| US-20100178342-A1 | Solid Pharmaceutical Preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20080200498-A1 | Pharmaceutical Composition For The Treatment Of Disorders Of Sexual Desire | CECI ANGELO | 2008-08-21 | — | — | US | disclosed |
| WO-2007028770-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS FOR NEUROPROTECTION IN PATIENTS SUFFERING FROM AN ADVANCED STAGE OF A MENTAL DISEASE | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028769-A1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR FOR NEUROPROTECTION | NEUROSEARCH A/S (DK) | 2007-03-15 | — | — | WO | disclosed |
| US-20050277664-A1 | Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050154009-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154009-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | SLC18A3, ACHE, SLC6A2 | AHR 1468/4885CD274 2924/4885PTGER1 3308/4885 |
| US-20080200498-A1 | Pharmaceutical Composition For The Treatment Of Disorders Of Sexual Desire | SLC18A2, SLC6A3, SLC6A2 | AHR 2440/4885CD274 3653/4885PTGER1 1954/4885 |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | SLC18A2, SLC6A2, SLC6A3 | AHR 794/4885CD274 1158/4885PTGER1 2247/4885 |
| US-20050277664-A1 | Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation | SLC6A2, SLC18A2, SLC18A3 | AHR 1191/4885CD274 3064/4885PTGER1 4209/4885 |
| US-20100178342-A1 | Solid Pharmaceutical Preparation | SLC6A2, SLC18A2, SLC6A3 | AHR 720/4885CD274 3665/4885PTGER1 1823/4885 |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | SLC6A2, SLC6A3, SLC6A4 | AHR 943/4885CD274 3492/4885PTGER1 4490/4885 |
| US-20100210626-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | SLC18A3, SLC6A2, SLC18A2 | AHR 1377/4885CD274 3011/4885PTGER1 3249/4885 |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | SLC6A2, SLC6A3, SLC18A2 | AHR 671/4885CD274 1352/4885PTGER1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.